RELAPSING REMITTING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING REMITTING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING REMITTING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a stem cell transplant stop MS in its tracks?
Disease control Recruiting nowThis study compares a stem cell transplant (AHSCT) to the best standard treatments for people with relapsing multiple sclerosis that hasn't responded to other therapies. About 156 participants will be randomly assigned to one of the two groups and followed for six years. The goal…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
Could a tiny neck implant help repair nerve damage in MS?
Disease control Recruiting nowThis study tests a small device implanted on the vagus nerve in the neck to see if it can safely help repair myelin (the protective coating around nerves) in people with relapsing-remitting multiple sclerosis (RRMS). About 60 adults aged 22-50 will receive the implant; two-thirds…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: NA • Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Cheaper MS drug could be just as effective as pricey alternative
Disease control Recruiting nowThis study compares two drugs, rituximab and ocrelizumab, for people with relapsing-remitting multiple sclerosis (MS). The goal is to see if rituximab works as well as ocrelizumab at preventing MS attacks and new brain lesions over two years. About 386 adults aged 18-55 with acti…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Rennes University Hospital • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Could a cancer drug tame multiple sclerosis? new trial launches
Disease control Recruiting nowThis study tests whether a drug called ixazomib, currently used for cancer, is safe for people with multiple sclerosis (MS). About 72 adults with relapsing-remitting or progressive MS will take either ixazomib capsules or a placebo for up to 24 months. Researchers will monitor si…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
Scientists track immune changes in MS patients on B-Cell drugs
Knowledge-focused Recruiting nowThis study follows 100 people with relapsing-remitting multiple sclerosis who are taking B-cell therapies like ofatumumab or ocrelizumab. Researchers will regularly check their immune cells, proteins, and brain scans to see how these treatments affect the body over time. The goal…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Knowledge-focused
Last updated May 17, 2026 04:10 UTC
-
Can a smart app improve MS care? new study seeks answers
Knowledge-focused Recruiting nowThis study is testing a new digital platform designed to help doctors and patients track multiple sclerosis (MS) over time. About 500 people with relapsing-remitting MS and their healthcare providers will use the platform for two years. The goal is to see if the tool is easy to u…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated May 11, 2026 20:47 UTC